Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02793765
Title Docetaxel Followed by Provenge in Metastatic Prostate Cancer
Recruitment Withdrawn
Gender male
Phase Phase II
Variant Requirements No
Sponsors The University of Texas Health Science Center, Houston

prostate adenocarcinoma


Docetaxel + Sipuleucel-T

Age Groups: adult
Covered Countries USA

No variant requirements are available.